EVALUATION OF THE EFFICACY AND SAFETY OF OTAMIXABAN VS. UNFRACTIONATED HEPARIN+EPTIFIBATIDE IN ELDERLY PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROMES IN THE SEPIA-ACS1 TIMI 42 TRIAL

MLA

Ruff, Christian T., et al. “Evaluation of the Efficacy and Safety of Otamixaban Vs. Unfractionated Heparin+Eptifibatide in Elderly Patients with Non-St-Elevation Acute Coronary Syndromes in the Sepia-Acs1 Timi 42 Trial.” Journal of the American College of Cardiology (JACC), vol. 57, Apr. 2011, p. E915. EBSCOhost, https://doi.org/10.1016/S0735-1097(11)60915-7.

APA

Ruff, C. T., Goodman, S., Hod, H., Bode, C., Widimsky, P., Kiss, R. G., Contant, C. F., Crugnale, S. E., Moryusef, A., Steg, G., Antman, E. M., & Sabatine, M. S. (2011). Evaluation of the Efficacy and Safety of Otamixaban Vs. Unfractionated Heparin+Eptifibatide in Elderly Patients with Non-St-Elevation Acute Coronary Syndromes in the Sepia-Acs1 Timi 42 Trial. Journal of the American College of Cardiology (JACC), 57, E915. https://doi.org/10.1016/S0735-1097(11)60915-7

Chicago

Ruff, Christian T., Shaun Goodman, Hanoch Hod, Christoph Bode, Petr Widimsky, Robert G. Kiss, Charles F. Contant, et al. 2011. “Evaluation of the Efficacy and Safety of Otamixaban Vs. Unfractionated Heparin+Eptifibatide in Elderly Patients with Non-St-Elevation Acute Coronary Syndromes in the Sepia-Acs1 Timi 42 Trial.” Journal of the American College of Cardiology (JACC) 57 (April): E915. doi:10.1016/S0735-1097(11)60915-7.